Tacrolimus 0.1% for Vitiligo: Efficacy by Zone (Face/Neck vs Trunk vs Acral) — Evidence Overview
Key Takeaways Face/neck respond fastest: perifollicular islands in 4–8 weeks, meaningful F-VASI drops by 8–12 weeks—best as nightly monotherapy or […]
tacrolimus 0.1%
Tacrolimus 0.1% in Vitiligo: Efficacy by Site (Face/Neck vs Trunk vs Acral) — Evidence Overview
Key Takeaways Face/neck respond best to tacrolimus 0.1%, with earlier perifollicular islands and higher chances of achieving F-VASI50/75 when combined
Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone (Face/Neck vs Trunk vs Acral)
Key Takeaways Highest efficacy on face/neck with early perifollicular islands; moderate on trunk/limbs; limited on acral sites without phototherapy add-ons.
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Face/neck consistently show the best repigmentation with tacrolimus 0.1%; early perifollicular islands predict response. Acral (hands/feet) and longstanding
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities